Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 6/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22062686 | 0.80 | DPP4 (0.46) | GLSMGAMGAASIMGAM2 | |
| SCHEMBL19303001 | 0.79 | ACHE (0.43) | GLSMGAMGAASIMGAM2 | |
| SCHEMBL18270228 | 0.78 | NAMPT (0.40) | GLSMGAMGAASIMGAM2 | |
| SCHEMBL19400511 | 0.77 | GLS (0.45) | PSMB8PSMB9PSMB5GLS | |
| SCHEMBL18896161 | 0.77 | KDM4E (0.42) | PSMB8PSMB9PSMB5GLSTSHR | |
| SCHEMBL21210621 | 0.73 | PSMB8 (0.39) | PSMB8PSMB9PSMB5GLSTSHR | |
| SCHEMBL4781030 | 0.72 | MGAM (0.56) | GLSMGAMGAASIMGAM2 | |
| SCHEMBL4781660 | 0.70 | GLS (0.41) | GLSMGAMGAASIMGAM2 | |
| SCHEMBL4780340 | 0.69 | DPP4 (0.42) | GLSMGAMGAASIMGAM2 | |
| SCHEMBL31162032 | 0.69 | GLS (0.53) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | PSMB8 1337/4885PSMB9 3021/4885PSMB5 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.